The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin

Diabetologia
J E TookeA C Shore

Abstract

Insulin resistance is associated with abnormal microvascular function. Treatment with insulin sensitisers may provoke oedema, suggesting microvascular effects. The mechanisms underlying the peripheral oedema observed during glucose-lowering treatment with thiazolidinediones are unclear. Therefore we examined the effect of pioglitazone on microvascular variables involved in oedema formation. Subjects (40-80 years) with type 2 diabetes and on insulin were randomised to 9 weeks of pioglitazone therapy (30 mg/day; n=14) or placebo (n=15). The following assessments were performed at baseline and 9 weeks: microvascular filtration capacity; isovolumetric venous pressure; capillary pressure; capillary recruitment following venous or arterial occlusion; postural vasoconstriction; and maximum blood flow. A number of haematological variables were also measured including vascular endothelium growth factor (VEGF), IL-6 and C-reactive protein (CRP). Pioglitazone did not significantly influence any microcirculatory variable as compared with placebo (analysis of covariance [ANCOVA] for microvascular filtration capacity for the two groups, p=0.26). Mean VEGF increased with pioglitazone (61.1 pg/ml), but not significantly more than placebo (9.76...Continue Reading

References

Jan 1, 1990·Clinical Science·A A HassanJ E Tooke
Oct 1, 1988·Clinical Science·A A Hassan, J E Tooke
Jan 1, 1994·Archives of Disease in Childhood·A C ShoreJ E Tooke
Dec 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·A J JaapJ E Tooke
Oct 10, 1998·Kidney International·D M LewisA C Shore
May 3, 2000·Journal of Internal Medicine·J E Tooke, M M Hannemann
Aug 2, 2000·Annals of Nuclear Medicine·G Tsujimoto
Sep 27, 2000·Journal of Diabetes and Its Complications·J E Tooke
May 22, 2002·JAMA : the Journal of the American Medical Association·Tien Yin WongUNKNOWN ARIC Investigators
Jul 20, 2002·Pharmacotherapy·Nancee V Niemeyer, Laurel M Janney
Nov 28, 2002·Diabetes·Michelle G WallisMichael G Clark
Oct 30, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sunder MudaliarRobert R Henry
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Priya MohantyParesh Dandona
Sep 16, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Nov 9, 2004·International Journal of Clinical Practice·G BelcherM Valbuena

❮ Previous
Next ❯

Citations

Mar 13, 2008·Diabetes, Obesity & Metabolism·R E Buckingham, A Hanna
May 29, 2008·Diabetes, Obesity & Metabolism·E MannucciN Marchionni
Jun 28, 2007·International Journal of Clinical Practice. Supplement·G Derosa
Jun 6, 2009·International Journal of Clinical Practice·G Schernthaner
May 11, 2011·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Catherine E QuinnGary E McVeigh
Sep 7, 2016·Pharmacology & Therapeutics·Ilia GoltsmanZaid Abassi
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.